Curi Bio develops biosystem platforms that integrate human cells and data to create 3D tissue models for drug discovery and disease modeling. Their technology enables accurate testing of drug safety and efficacy, addressing the challenges of predictive accuracy in preclinical drug development.
Funding
$10.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Preclinical drug development suffers from poor predictive accuracy, leading to costly late-stage failures due to inaccurate models for testing drug safety and efficacy. Traditional methods often fail to replicate the complexities of human biology, resulting in ineffective or unsafe compounds advancing to clinical trials.
Solution
Curi Bio offers biosystem platforms that integrate human cells, 3D tissue models, and data analytics to enhance drug discovery and disease modeling. Their integrated platform combines advanced 3D tissue models of disease, biosystems for clinically relevant functional analyses, and AI/ML-enabled insights. This approach enables researchers to merge functional and analytical assessments for improved drug safety, efficacy, and potency testing. Curi Bio's technology aims to provide more accurate, human-relevant data for better-informed R&D decision-making in the preclinical pipeline.
Target Audience
The primary customers are pharmaceutical companies, biotech firms, and research institutions involved in preclinical drug discovery and development, particularly those focused on cardiac and skeletal muscle diseases.
Features
- Mantarray™ platform for 3D tissue contractility analysis, providing high-throughput functional data
- Nautilai™ platform for optical mapping of voltage and calcium, enabling detailed electrophysiological studies
- Stingray™ platform for enhanced maturation of 3D engineered tissues, improving model fidelity
- Cytostretcher™ instruments for applying controlled mechanical stretch to cells, mimicking physiological conditions
- NanoSurface™ plates for structural maturation of cardiac and skeletal muscle cultures
- Pulse™ software for high-throughput video contractility analysis
- Curi Engine™ Services for custom assay development, disease model generation, and compound profiling
- Capability to create custom gene-edited iPSC models and differentiate them into myoblasts and cardiomyocytes